p53 and ki67 as biomarkers in determining response to chemoprevention for oral leukoplakia

Toru Nagao, Saman Warnakulasuriya, Hidenori Sakuma, Satoru Miyabe, Shogo Hasegawa, Junichiro Machida, Koji Suzuki, Hideo Fukano, Kazuo Shimozato, Shuji Hashimoto

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: We performed a randomized controlled chemoprevention trial of oral leukoplakia by administrating a low dose of beta-carotene and vitamin C supplements. 17% of subjects in the experimental arm (4/23) demonstrated clinical remission (complete or partial response) at completion of the trial. The objective of this study was to determine whether baseline expression of p53 and ki67 demonstrated any differences between those responding or not responding to our intervention. A secondary objective was to elucidate any relationship between dietary factors and clinical responses. Methods: For this biomarker study, we included all subjects in the experimental group (n = 23) who were non-smokers. Among 16 who completed the trial for 1 year of supplementation, there were four responders and 12 non-responders at 1-year follow-up. Following immuno-staining for p53 and ki67, the percentage of positive cell nuclei were analyzed as labeling index (LI). Results: Expression of p53 was greater in basal layers than in para-basal layers. Mean para-basal LI of p53 was higher in non-responding (26.0) than in responding subjects (11.2) (P = 0.028). ki67 LIs were not significantly different in the two groups. Conclusions: Expression of p53 was inversely related to clinical response to the supplements. Other biomarkers that may recognize subject's responsiveness to chemoprevention require further study.

Original languageEnglish
Pages (from-to)346-352
Number of pages7
JournalJournal of Oral Pathology and Medicine
Volume46
Issue number5
DOIs
Publication statusPublished - 01-05-2017

Fingerprint

Oral Leukoplakia
Chemoprevention
Biomarkers
beta Carotene
Cell Nucleus
Ascorbic Acid
Randomized Controlled Trials
Staining and Labeling

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine
  • Oral Surgery
  • Otorhinolaryngology
  • Cancer Research
  • Periodontics

Cite this

Nagao, Toru ; Warnakulasuriya, Saman ; Sakuma, Hidenori ; Miyabe, Satoru ; Hasegawa, Shogo ; Machida, Junichiro ; Suzuki, Koji ; Fukano, Hideo ; Shimozato, Kazuo ; Hashimoto, Shuji. / p53 and ki67 as biomarkers in determining response to chemoprevention for oral leukoplakia. In: Journal of Oral Pathology and Medicine. 2017 ; Vol. 46, No. 5. pp. 346-352.
@article{a5e9bc8e473c446da6932baac8acbe03,
title = "p53 and ki67 as biomarkers in determining response to chemoprevention for oral leukoplakia",
abstract = "Background: We performed a randomized controlled chemoprevention trial of oral leukoplakia by administrating a low dose of beta-carotene and vitamin C supplements. 17{\%} of subjects in the experimental arm (4/23) demonstrated clinical remission (complete or partial response) at completion of the trial. The objective of this study was to determine whether baseline expression of p53 and ki67 demonstrated any differences between those responding or not responding to our intervention. A secondary objective was to elucidate any relationship between dietary factors and clinical responses. Methods: For this biomarker study, we included all subjects in the experimental group (n = 23) who were non-smokers. Among 16 who completed the trial for 1 year of supplementation, there were four responders and 12 non-responders at 1-year follow-up. Following immuno-staining for p53 and ki67, the percentage of positive cell nuclei were analyzed as labeling index (LI). Results: Expression of p53 was greater in basal layers than in para-basal layers. Mean para-basal LI of p53 was higher in non-responding (26.0) than in responding subjects (11.2) (P = 0.028). ki67 LIs were not significantly different in the two groups. Conclusions: Expression of p53 was inversely related to clinical response to the supplements. Other biomarkers that may recognize subject's responsiveness to chemoprevention require further study.",
author = "Toru Nagao and Saman Warnakulasuriya and Hidenori Sakuma and Satoru Miyabe and Shogo Hasegawa and Junichiro Machida and Koji Suzuki and Hideo Fukano and Kazuo Shimozato and Shuji Hashimoto",
year = "2017",
month = "5",
day = "1",
doi = "10.1111/jop.12498",
language = "English",
volume = "46",
pages = "346--352",
journal = "Journal of Oral Pathology and Medicine",
issn = "0904-2512",
publisher = "Wiley-Blackwell",
number = "5",

}

Nagao, T, Warnakulasuriya, S, Sakuma, H, Miyabe, S, Hasegawa, S, Machida, J, Suzuki, K, Fukano, H, Shimozato, K & Hashimoto, S 2017, 'p53 and ki67 as biomarkers in determining response to chemoprevention for oral leukoplakia', Journal of Oral Pathology and Medicine, vol. 46, no. 5, pp. 346-352. https://doi.org/10.1111/jop.12498

p53 and ki67 as biomarkers in determining response to chemoprevention for oral leukoplakia. / Nagao, Toru; Warnakulasuriya, Saman; Sakuma, Hidenori; Miyabe, Satoru; Hasegawa, Shogo; Machida, Junichiro; Suzuki, Koji; Fukano, Hideo; Shimozato, Kazuo; Hashimoto, Shuji.

In: Journal of Oral Pathology and Medicine, Vol. 46, No. 5, 01.05.2017, p. 346-352.

Research output: Contribution to journalArticle

TY - JOUR

T1 - p53 and ki67 as biomarkers in determining response to chemoprevention for oral leukoplakia

AU - Nagao, Toru

AU - Warnakulasuriya, Saman

AU - Sakuma, Hidenori

AU - Miyabe, Satoru

AU - Hasegawa, Shogo

AU - Machida, Junichiro

AU - Suzuki, Koji

AU - Fukano, Hideo

AU - Shimozato, Kazuo

AU - Hashimoto, Shuji

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Background: We performed a randomized controlled chemoprevention trial of oral leukoplakia by administrating a low dose of beta-carotene and vitamin C supplements. 17% of subjects in the experimental arm (4/23) demonstrated clinical remission (complete or partial response) at completion of the trial. The objective of this study was to determine whether baseline expression of p53 and ki67 demonstrated any differences between those responding or not responding to our intervention. A secondary objective was to elucidate any relationship between dietary factors and clinical responses. Methods: For this biomarker study, we included all subjects in the experimental group (n = 23) who were non-smokers. Among 16 who completed the trial for 1 year of supplementation, there were four responders and 12 non-responders at 1-year follow-up. Following immuno-staining for p53 and ki67, the percentage of positive cell nuclei were analyzed as labeling index (LI). Results: Expression of p53 was greater in basal layers than in para-basal layers. Mean para-basal LI of p53 was higher in non-responding (26.0) than in responding subjects (11.2) (P = 0.028). ki67 LIs were not significantly different in the two groups. Conclusions: Expression of p53 was inversely related to clinical response to the supplements. Other biomarkers that may recognize subject's responsiveness to chemoprevention require further study.

AB - Background: We performed a randomized controlled chemoprevention trial of oral leukoplakia by administrating a low dose of beta-carotene and vitamin C supplements. 17% of subjects in the experimental arm (4/23) demonstrated clinical remission (complete or partial response) at completion of the trial. The objective of this study was to determine whether baseline expression of p53 and ki67 demonstrated any differences between those responding or not responding to our intervention. A secondary objective was to elucidate any relationship between dietary factors and clinical responses. Methods: For this biomarker study, we included all subjects in the experimental group (n = 23) who were non-smokers. Among 16 who completed the trial for 1 year of supplementation, there were four responders and 12 non-responders at 1-year follow-up. Following immuno-staining for p53 and ki67, the percentage of positive cell nuclei were analyzed as labeling index (LI). Results: Expression of p53 was greater in basal layers than in para-basal layers. Mean para-basal LI of p53 was higher in non-responding (26.0) than in responding subjects (11.2) (P = 0.028). ki67 LIs were not significantly different in the two groups. Conclusions: Expression of p53 was inversely related to clinical response to the supplements. Other biomarkers that may recognize subject's responsiveness to chemoprevention require further study.

UR - http://www.scopus.com/inward/record.url?scp=85018688711&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018688711&partnerID=8YFLogxK

U2 - 10.1111/jop.12498

DO - 10.1111/jop.12498

M3 - Article

C2 - 27605086

AN - SCOPUS:85018688711

VL - 46

SP - 346

EP - 352

JO - Journal of Oral Pathology and Medicine

JF - Journal of Oral Pathology and Medicine

SN - 0904-2512

IS - 5

ER -